Drugs to Prevent Bronchopulmonary Dysplasia: Effect of Baseline Risk on the Number Needed to Treat

Erik A Jensen; Robin S Roberts; Barbara Schmidt

doi:10.1016/j.jpeds.2020.01.070

Drugs to Prevent Bronchopulmonary Dysplasia: Effect of Baseline Risk on the Number Needed to Treat

J Pediatr. 2020 Jul:222:244-247. doi: 10.1016/j.jpeds.2020.01.070. Epub 2020 Mar 3.

Authors

Erik A Jensen¹, Robin S Roberts², Barbara Schmidt³

Affiliations

¹ Division of Neonatology, Department of Pediatrics, The Children's Hospital of Philadelphia, Philadelphia, PA; Department of Pediatrics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA. Electronic address: jensene@email.chop.edu.
² Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada.
³ Department of Pediatrics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA; Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada.

PMID: 32143932
DOI: 10.1016/j.jpeds.2020.01.070

Abstract

Infants born very preterm have a variable baseline risk of bronchopulmonary dysplasia (BPD). Using the example of evidence-based drug therapies to prevent BPD, we designed a visual aid that displays the "number needed to treat" with CIs for caffeine, vitamin A, and hydrocortisone over a range of baseline risks.

Keywords: NNT; baseline risk; caffeine; chronic lung disease; evidence-based medicine; hydrocortisone; vitamin A.

Publication types

Meta-Analysis
Review

MeSH terms

Anti-Inflammatory Agents / pharmacology
Bronchopulmonary Dysplasia / prevention & control*
Caffeine / pharmacology*
Evidence-Based Medicine / methods*
Glucocorticoids / pharmacology*
Humans
Hydrocortisone / pharmacology*
Infant, Newborn
Infant, Premature*
Phosphodiesterase Inhibitors / pharmacology
Vitamin A / pharmacology*
Vitamins / pharmacology

Substances

Anti-Inflammatory Agents
Glucocorticoids
Phosphodiesterase Inhibitors
Vitamins
Vitamin A
Caffeine
Hydrocortisone